Diabetes Care, Vol 17, Issue 8 909-917, Copyright © 1994 by American Diabetes Association

ARTICLES

Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform

JC Javitt, LP Aiello, Y Chiang, FL Ferris, JK Canner and S Greenfield
Worthen Center for Eye Care Research, Georgetown University Medical Center, Washington, DC.

OBJECTIVE--Diabetic retinopathy, which leads to macular edema and retinal neovascularization, is the leading cause of blindness among working-age Americans. Previous research has demonstrated significant cost savings associated with detection of eye disease in Americans with type I diabetes. However, detection and treatment of eye disease among those with type II diabetes was previously thought not to be cost-saving. Our purpose was to estimate the current and potential federal savings resulting from the screening and treatment of retinopathy in patients with type II diabetes, based on recently available data concerning efficacy of treating both macular edema and neovascularization along with new data on federal budgetary costs of blindness. RESEARCH DESIGN AND METHODS--We used computer modeling, incorporating data from population-based epidemiological studies and multicenter clinical trials. Monte Carlo simulation was used, combined with sensitivity analysis and present value analysis of cost savings. RESULTS--Screening and treatment for eye disease in patients with type II diabetes generates annual savings of $247.9 million to the federal budget and 53,986 person-years of sight, even at current suboptimal (60%) levels of care. If all patients with type II diabetes receive recommended care, the predicted net savings (discounted at 5%) exceeds $472.1 million and 94,304 person-years of sight. Nearly all savings are associated with detection and treatment of diabetic macular edema. Enrolling each additional person with type II diabetes into currently recommended ophthalmological care results in an average net savings of $975/person, even if all costs of care are borne by the federal government. CONCLUSIONS--Our analysis indicates that prevention programs aimed at improving eye care for patients with diabetes not only reduce needless vision loss but also will provide a financial return on the investment of public funds.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. B. Saaddine, A. A. Honeycutt, K. M. V. Narayan, X. Zhang, R. Klein, and J. P. Boyle Projection of Diabetic Retinopathy and Other Major Eye Diseases Among People With Diabetes Mellitus: United States, 2005-2050 Arch Ophthalmol, December 1, 2008; 126(12): 1740 - 1747. [Abstract] [Full Text] [PDF]

				E Olafsdottir and E Stefansson Biennial eye screening in patients with diabetes without retinopathy: 10-year experience Br. J. Ophthalmol., December 1, 2007; 91(12): 1599 - 1601. [Abstract] [Full Text] [PDF]

				G S Scotland, P McNamee, S Philip, A D Fleming, K A Goatman, G J Prescott, S Fonseca, P F Sharp, and J A Olson Cost-effectiveness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland Br. J. Ophthalmol., November 1, 2007; 91(11): 1518 - 1523. [Abstract] [Full Text] [PDF]

				K. R. Tuttle, J. B. McGill, D. J. Haney, T. E. Lin, P. W. Anderson, and for the PKC-DRS, PKC-DMES, and PKC-DRS 2 Study Gro Kidney Outcomes in Long-Term Studies of Ruboxistaurin for Diabetic Eye Disease Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 631 - 636. [Abstract] [Full Text] [PDF]

				D. C. Kendrick, D. Bu, E. Pan, and B. Middleton Crossing the Evidence Chasm: Building Evidence Bridges from Process Changes to Clinical Outcomes J. Am. Med. Inform. Assoc., May 1, 2007; 14(3): 329 - 339. [Abstract] [Full Text] [PDF]

				The PKC-DMES Study Group Effect of Ruboxistaurin in Patients With Diabetic Macular Edema: Thirty-Month Results of the Randomized PKC-DMES Clinical Trial Arch Ophthalmol, March 1, 2007; 125(3): 318 - 324. [Abstract] [Full Text] [PDF]

				J. B. Saaddine, B. Cadwell, E. W. Gregg, M. M. Engelgau, F. Vinicor, G. Imperatore, and K. M. V. Narayan Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 1988-2002 Ann Intern Med, April 4, 2006; 144(7): 465 - 474. [Abstract] [Full Text] [PDF]

				D. S. Fong, L. P. Aiello, F. L. Ferris III, and R. Klein Diabetic Retinopathy Diabetes Care, October 1, 2004; 27(10): 2540 - 2553. [Full Text] [PDF]

				H Murgatroyd, A Ellingford, A Cox, M Binnie, J D Ellis, C J MacEwen, and G P Leese Effect of mydriasis and different field strategies on digital image screening of diabetic eye disease Br. J. Ophthalmol., July 1, 2004; 88(7): 920 - 924. [Abstract] [Full Text] [PDF]

				N. Aoki, K. Dunn, T. Fukui, J. R. Beck, W. J. Schull, and H. K. Li Cost-Effectiveness Analysis of Telemedicine to Evaluate Diabetic Retinopathy in a Prison Population Diabetes Care, May 1, 2004; 27(5): 1095 - 1101. [Abstract] [Full Text] [PDF]

				J. Orcutt, A. Avakian, T. D. Koepsell, and C. Maynard Eye Disease in Veterans With Diabetes Diabetes Care, May 1, 2004; 27(suppl_2): B50 - B53. [Abstract] [Full Text] [PDF]

				C. T. Sawin, D. J. Walder, D. S. Bross, and L. M. Pogach Diabetes Process and Outcome Measures in the Department of Veterans Affairs Diabetes Care, May 1, 2004; 27(suppl_2): B90 - B94. [Abstract] [Full Text] [PDF]

				D. Fetterolf and R. West The Business Case for Quality: Combining Medical Literature Research with Health Plan Data to Establish Value for Nonclinical Managers American Journal of Medical Quality, March 1, 2004; 19(2): 48 - 55. [Abstract] [PDF]

				C Meads and C Hyde What is the cost of blindness? Br. J. Ophthalmol., October 1, 2003; 87(10): 1201 - 1204. [Full Text] [PDF]

				J. B. Brown, K. L. Pedula, and K. H. Summers Diabetic Retinopathy: Contemporary prevalence in a well-controlled population Diabetes Care, September 1, 2003; 26(9): 2637 - 2642. [Abstract] [Full Text] [PDF]

				D M Squirrell and J F Talbot Screening for diabetic retinopathy J R Soc Med, June 1, 2003; 96(6): 273 - 276. [Full Text] [PDF]

				G L Ong, L G Ripley, R S B Newsom, and A G Casswell Assessment of colour vision as a screening test for sight threatening diabetic retinopathy before loss of vision Br. J. Ophthalmol., June 1, 2003; 87(6): 747 - 752. [Abstract] [Full Text] [PDF]

				F. Gomez-Ulla, M. I. Fernandez, F. Gonzalez, P. Rey, M. Rodriguez, M. J. Rodriguez-Cid, F. F. Casanueva, M. A. Tome, J. Garcia-Tobio, and F. Gude Digital Retinal Images and Teleophthalmology for Detecting and Grading Diabetic Retinopathy Diabetes Care, August 1, 2002; 25(8): 1384 - 1389. [Abstract] [Full Text] [PDF]

				W. Jackson Improving Diabetic Retinopathy Screening Diabetes Care, August 1, 2002; 25(8): 1477 - 1478. [Full Text] [PDF]

				J. B. Saaddine, M. M. Engelgau, G. L. Beckles, E. W. Gregg, T. J. Thompson, and K.M. V. Narayan A Diabetes Report Card for the United States: Quality of Care in the 1990s Ann Intern Med, April 16, 2002; 136(8): 565 - 574. [Abstract] [Full Text] [PDF]

				The Translating Research Into Action for Diabetes (TRIAD) Study: A multicenter study of diabetes in managed care Diabetes Care, February 1, 2002; 25(2): 386 - 389. [Full Text] [PDF]

				T. Qaum, Q. Xu, A. M. Joussen, M. W. Clemens, W. Qin, K. Miyamoto, H. Hassessian, S. J. Wiegand, J. Rudge, G. D. Yancopoulos, et al. VEGF-initiated Blood-Retinal Barrier Breakdown in Early Diabetes Invest. Ophthalmol. Vis. Sci., September 1, 2001; 42(10): 2408 - 2413. [Abstract] [Full Text] [PDF]

				J. M. Robbins and P. Holland Passage of Policy Statement on the High Risk of Blindness, Lower-Extremity Amputations, and Oral Health Consequences in Minority Populations Due to Diabetes J Am Podiatr Med Assoc, June 1, 2001; 91(6): 313 - 315. [Full Text] [PDF]

				D. S. Fong, J. Gottlieb, F. L. Ferris III, and R. Klein Understanding the Value of Diabetic Retinopathy Screening Arch Ophthalmol, May 1, 2001; 119(5): 758 - 760. [Full Text] [PDF]

				H. R Taylor and J. E Keeffe World blindness: a 21st century perspective Br. J. Ophthalmol., March 1, 2001; 85(3): 261 - 266. [Full Text]

				J. C. Javitt, G. C. Brown, M. M. Brown, S. Sharma, H. D. Hoskins, Jr, S. Vijan, T. P. Hofer, and R. A. Hayward How Often Should Patients With Diabetes Be Screened for Retinopathy? JAMA, July 26, 2000; 284(4): 437 - 439. [Full Text] [PDF]

				A. Melville, R. Richardson, J. Mason, A. McIntosh, C. O'Keeffe, J. Peters, and A. Hutchinson Complications of diabetes: screening for retinopathy and management of foot ulcers Qual. Saf. Health Care, June 1, 2000; 9(2): 137 - 141. [Full Text]

				S. Vijan, T. P. Hofer, and R. A. Hayward Cost-Utility Analysis of Screening Intervals for Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus JAMA, February 16, 2000; 283(7): 889 - 896. [Abstract] [Full Text] [PDF]

				F. L. Ferris, M. D. Davis, and L. M. Aiello Treatment of Diabetic Retinopathy N. Engl. J. Med., August 26, 1999; 341(9): 667 - 678. [Full Text] [PDF]

				H L Cook, R Newsom, V Long, S A Smith, J S Shilling, and M R Stanford Natural history of diabetic macular streak exudates: evidence from a screening programme Br. J. Ophthalmol., May 1, 1999; 83(5): 563 - 566. [Abstract] [Full Text]

				The CDC Diabetes Cost-Effectiveness Study Group The Cost-effectiveness of Screening for Type 2 Diabetes JAMA, November 25, 1998; 280(20): 1757 - 1763. [Abstract] [Full Text] [PDF]

				S. K. Kraft, D. G. Marrero, E. N. Lazaridis, N. Fineberg, C. Qiu, and C. M. Clark Jr Primary Care Physicians' Practice Patterns and Diabetic Retinopathy: Current Levels of Care Arch Fam Med, January 1, 1997; 6(1): 29 - 37. [Abstract] [PDF]

				J. C. Javitt and L. P. Aiello Cost-Effectiveness of Detecting and Treating Diabetic Retinopathy Ann Intern Med, January 1, 1996; 124(1_Part_2): 164 - 169. [Abstract] [Full Text]

				A. Parnaby-Price Screening for diabetic retinopathy BMJ, November 4, 1995; 311(7014): 1229a - 1229. [Full Text]